AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2003 SEP 3 - (NewsRx.com & NewsRx.net) -- Canarypox virus is a safe vector for use in human p53 cancer vaccine.
"Overexpression of p53 occurs in more than 50% of colorectal cancers. Therefore, p53 represents an attractive target antigen for immunotherapy. We assessed the safety of a canarypox virus encoding the human wild-type p53 gene given intravenously to end-stage colorectal cancer patients in a three-step dose escalation study aimed at inducing p53 immune responses," scientists in the Netherlands reported.
"Patients with metastatic disease of p53-overexpressing colorectal cancers were vaccinated three times at 3-week intervals, each time with 10(6.5) CCID50 (CCID50=cell culture infectious dose 50%; group 1, n=5), 10(7.0) CCID50 (group 2, n=5) or 10(7.5) CCID50 (group 3, n=6). Vital signs and the occurrence of adverse events were monitored and blood was analyzed for biochemical and hematological parameters as well as signs of autoimmune safety," said A.G. Menon and colleagues, Leiden University, Medical Center.
"In all, 16 patients were enrolled and 15 patients completed three vaccinations. No anaphylactic reaction or unwanted autoimmune reactions were observed. A total of 16 serious adverse events (SAEs) occurred: 10 in group 1, three in group 2 and three in group 3. All SAEs were tumor-related complications," study authors noted.
"There was no difference in the frequency of adverse events between the three groups, except for fever. Fever was the only vaccination-related adverse event ...